Elevated platelet expression of CD36 may contribute to increased risk of thrombo-embolism in active inflammatory bowel disease

References

• Alkhatatbeh MJ, Mhaidat NM, Enjeti AK, et al. (2011). The putative diabetic plasma marker, soluble CD36, is non-cleaved, non-soluble and entirely associated with microparticles. J Thromb Haemost, 9:844–51
   PubMed Web of Science ®Google Scholar
• Andoh A, Tsujikawa T, Hata K, et al. (2005). Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol, 100:2042–8
   PubMed Web of Science ®Google Scholar
• Andoh A, Yoshida T, Yagi Y, et al. (2006). Increased aggregation response of platelets in patients with inflammatory bowel disease. J Gastroenterol, 41:47–54
   PubMed Web of Science ®Google Scholar
• Bahijri SM, Alissa EM, Akbar DH, Ghabrah TM. (2010). Estimation of insulin resistance in non-diabetic normotensive Saudi adults by QUICKI, HOMA-IR and modified QUICKI: a comparative study. Ann Saudi Med, 30:257–64
   PubMed Web of Science ®Google Scholar
• Boyer JF, Balard P, Authier H, et al. (2007) Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther, 9:2, R22
   Google Scholar
• Bregenzer N, Hartmann A, Strauch U, et al. (2006). Increased insulin resistance and beta cell activity in patients with Crohn’s disease. Inflamm Bowel Dis, 12:53–6
   PubMed Web of Science ®Google Scholar
• Chamouard P, Desprez D, Hugel B, et al. (2005). Circulating cell-derived microparticles in Crohn’s disease. Dig Dis Sci, 50:574–80
   PubMed Web of Science ®Google Scholar
• Cornillie F, Shealy D, D’Haens G, et al. (2001). Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther, 15:463–73
   PubMed Web of Science ®Google Scholar
• Danese S, Semeraro S, Papa A, et al. (2005). Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol, 11:7227–36
   PubMed Web of Science ®Google Scholar
• Daviet L, Malvoisin E, Wild TF, McGregor JL. (1997). Thrombospondin induces dimerization of membrane-bound, but not soluble CD36. Thromb Haemost, 78:897–901
   PubMed Web of Science ®Google Scholar
• Dorn SD, Sandler RS. (2007). Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol, 102:662–7
   PubMed Web of Science ®Google Scholar
• Dzik WH, Cserti-Gazdewich CM, Ssewanyana I, et al. (2010). When monocytes and platelets compete: The effect of platelet count on the flow cytometric measurement of monocyte CD36. Cytometry B Clin Cytom, 78:81–7
   PubMedGoogle Scholar
• Febbraio M, Hajjar DP, Silverstein RL. (2001). CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest, 108:785–91
   PubMed Web of Science ®Google Scholar
• Ghosh A, Li W, Febbraio M, et al. (2008). Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest, 118:1934–43
   PubMed Web of Science ®Google Scholar
• Glintborg D, Hojlund K, Andersen M, et al. (2008). Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment. Diabetes Care, 31:328–34
   PubMed Web of Science ®Google Scholar
• Grip O, Janciauskiene S, Lindgren S. (2004). Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm Bowel Dis, 10:193–200
   PubMed Web of Science ®Google Scholar
• Handberg A, Levin K, Hojlund K, Beck-Nielsen H. (2006). Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation, 114:1169–76
   PubMed Web of Science ®Google Scholar
• Handberg A, Skjelland M, Michelsen AE, et al. (2008). Soluble CD36 in plasma is increased in patients with symptomatic atherosclerotic carotid plaques and is related to plaque instability. Stroke, 39:3092–5
   PubMed Web of Science ®Google Scholar
• Handberg A, Lopez-Bermejo A, Bassols J, et al. (2009). Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men. Diab Vasc Dis Res, 6:15–20
   PubMed Web of Science ®Google Scholar
• Jess T, Loftus Jr EV, Harmsen WS, et al. (2006). Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004. Gut, 55:1248–54
   PubMed Web of Science ®Google Scholar
• Jess T, Gamborg M, Munkholm P, Sorensen TI. (2007). Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies. Am J Gastroenterol, 102:609–17
   PubMed Web of Science ®Google Scholar
• Khovidhunkit W, Kim MS, Memon RA, et al. (2004). Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res, 45:1169–96
   PubMed Web of Science ®Google Scholar
• Korporaal SJ, Van Eck M, Adelmeijer J, et al. (2007). Platelet activation by oxidized low density lipoprotein is mediated by CD36 and scavenger receptor-A. Arterioscler Thromb Vasc Biol, 27:2476–83
   PubMed Web of Science ®Google Scholar
• Levy E, Rizwan Y, Thibault L, et al. (2000). Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr, 71:807–15
   PubMed Web of Science ®Google Scholar
• Nergiz-Unal R, Lamers MM, Van Kruchten R, et al. (2011). Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. J Thromb Haemost, 9:1835–46
   PubMed Web of Science ®Google Scholar
• Nomura S, Ozaki Y, Ikeda Y. (2008). Function and role of microparticles in various clinical settings. Thromb Res, 123:8–23
   PubMed Web of Science ®Google Scholar
• Pattanapanyasat K, Gonwong S, Chaichompoo P, et al. (2007). Activated platelet-derived microparticles in thalassaemia. Br J Haematol, 136:462–71
   PubMed Web of Science ®Google Scholar
• Podolsky DK. (2002). Inflammatory bowel disease. N Engl J Med, 347:417–29
   PubMed Web of Science ®Google Scholar
• Salah-Uddin H, Gordon MJ, Ford I, et al. (2002). Surface expression of fatty acid translocase (FAT/CD36) on platelets in myeloproliferative disorders and non-insulin dependent diabetes mellitus: effect on arachidonic acid uptake. Mol Cell Biochem, 239:203–11
   PubMed Web of Science ®Google Scholar
• Silverstein RL, Febbraio M. (2000). CD36 and atherosclerosis. Curr Opin Lipidol, 11:483–91
   PubMed Web of Science ®Google Scholar
• Silverstein RL. (2009a). Inflammation, atherosclerosis, and arterial thrombosis: role of the scavenger receptor CD36. Cleve Clin J Med, 76:S27–30
   PubMedGoogle Scholar
• Silverstein RL. (2009b). Type 2 scavenger receptor CD36 in platelet activation: the role of hyperlipemia and oxidative stress. Clin Lipidol, 4:767
   PubMed Web of Science ®Google Scholar
• Tytgat NJG, Tytgat HAJS. (2008). Grading and Staging in Gastroenterology. 1st edn. New York, NY: Thieme
   Google Scholar
• Ursini F, Naty S, Grembiale RD. (2010). Infliximab and insulin resistance. Autoimmun Rev, 9:536–9
   PubMed Web of Science ®Google Scholar
• van Leuven SI, Hezemans R, Levels JH, et al. (2007). Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn’s disease. J Lipid Res, 48:2640–46
   PubMed Web of Science ®Google Scholar
• van Wersch JW, Houben P, Rijken J. (1990). Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem, 28:513–17
   PubMedGoogle Scholar
• Wang H, Wang ZH, Kong J, et al. (2011). Oxidized low-density lipoprotein-dependent platelet-derived microvesicles trigger procoagulant effects and amplify oxidative stress. Mol Med, 18:159–166
   Web of Science ®Google Scholar